|
1
|
Marina N, Gebhardt M, Teot L and Gorlick
R: Biology and therapeutic advances for pediatric osteosarcoma.
Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferguson WS and Goorin AM: Current
treatment of osteosarcoma. Cancer Investigation. 19:292–315. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schwartz CL, Gorlick R, Teot L, Krailo M,
Chen Z, Goorin A, Grier HE, Bernstein ML and Meyers P: Children's
Oncology Group: Multiple drug resistance in osteogenic sarcoma:
INT0133 from the children's oncology group. J Clin Oncol.
25:2057–2062. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marcove RC, Miké V, Hajek JV, Levin AG and
Hutter RV: Osteogenic sarcoma under the age of twenty-one. A review
of one hundred and forty-five operative cases. J Bone Joint Surg
Am. 52:411–423. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Friedman MA and Carter SK: The therapy of
osteogenic sarcoma: Current status and thoughts for the future. J
Surg Oncol. 4:482–510. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bernthal NM, Federman N, Eilber FR, Nelson
SD, Eckardt JJ, Eilber FC and Tap WD: Long-term results (>25
years) of a randomized, prospective clinical trial evaluating
chemotherapy in patients with high-grade, operable osteosarcoma.
Cancer. 118:5888–5893. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang J and Zhang W: New molecular insights
into osteosarcoma targeted therapy. Curr Opin Oncol. 25:398–406.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bruland OS and Pihl A: On the current
management of osteosarcoma. A critical evaluation and a proposal
for a modified treatment strategy. Eur J Cancer. 33:1725–1731.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Amankwah EK, Conley AP and Reed DR:
Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol.
5:147–162. 2013.PubMed/NCBI
|
|
10
|
Rainusso N, Wang LL and Yustein JT: The
adolescent and young adult with cancer: State of the art-bone
tumors. Curr Oncol Rep. 15:296–307. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cote GM and Choy E: Role of epigenetic
modulation for the treatment of sarcoma. Curr Treat Options Oncol.
14:454–464. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zamore PD and Haley B: Ribo-gnome: The big
world of small RNAs. Science. 309:1519–1524. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cho WC: OncomiRs: The discovery and
progress of microRNAs in cancers. Mol Cancer. 6:602007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim JG, Kim TO, Bae JH, Shim JW, Kang MJ,
Yang K, Ting AH and Yi JM: Epigenetically regulated MIR941 and
MIR1247 target gastric cancer cell growth and migration.
Epigenetics. 9:1018–1030. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fang L, Li H, Wang L, Hu J, Jin T, Wang J
and Yang BB: MicroRNA-17-5p promotes chemotherapeutic drug
resistance and tumour metastasis of colorectal cancer by repressing
PTEN expression. Oncotarget. 5:2974–2987. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Okudela K, Tateishi Y, Umeda S, Mitsui H,
Suzuki T, Saito Y, Woo T, Tajiri M, Masuda M, Miyagi Y and Ohashi
K: Allelic imbalance in the miR-31 host gene locus in lung
cancer-its potential role in carcinogenesis. PLoS One.
9:e1005812014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jin M, Zhang T, Liu C, Badeaux MA, Liu B,
Liu R, Jeter C, Chen X, Vlassov AV and Tang DG: MicroRNA-128
suppresses prostate cancer by inhibiting BMI-1 to inhibit
tumor-initiating cells. Cancer Res. 74:4183–4195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao Y, Luo LH, Li S and Yang C: miR-17
inhibitor suppressed osteosarcoma tumor growth and metastasis via
increasing PTEN expression. Biochem Biophys Res Commun.
444:230–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Browne G, Taipaleenmäki H, Stein GS, Stein
JL and Lian JB: MicroRNAs in the control of metastatic bone
disease. Trends Endocrinol Metab. 25:320–327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mulrane L, McGee SF, Gallagher WM and
O'Connor DP: miRNA dysregulation in breast cancer. Cancer Res.
73:6554–6562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bihrer V, Friedrich-Rust M, Kronenberger
B, Forestier N, Haupenthal J, Shi Y, Peveling-Oberhag J, Radeke HH,
Sarrazin C, Herrmann E, et al: Serum miR-122 as a biomarker of
necroinflammation in patients with chronic hepatitis C virus
infection. Am J Gastroenterol. 106:1663–1669. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bryant RJ, Pawlowski T, Catto JW, Marsden
G, Vessella RL, Rhees B, Kuslich C, Visakorpi T and Hamdy FC:
Changes in circulating microRNA levels associated with prostate
cancer. Br J Cancer. 106:768–774. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Joosse SA, Müller V, Steinbach B, Pantel K
and Schwarzenbach H: Circulating cell-free cancer-testis MAGE-A
RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with
breast cancer and benign breast diseases. Br J Cancer. 111:909–917.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Minami Y, Kohsaka S, Tsuda M, Yachi K,
Hatori N, Tanino M, Kimura T, Nishihara H, Minami A, Iwasaki N and
Tanaka S: SS18-SSX-regulated miR-17 promotes tumor growth of
synovial sarcoma by inhibiting p21WAF1/CIP1. Cancer Sci.
105:1152–1159. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li X, Yang H, Tian Q, Liu Y and Weng Y:
Upregulation of microRNA-17-92 cluster associates with tumor
progression and prognosis in osteosarcoma. Neoplasma. 61:453–460.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zampetaki A, Kiechl S, Drozdov I, Willeit
P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E,
et al: Plasma microRNA profiling reveals loss of endothelial
mir-126 and other microRNAs in type 2 diabetes. Circ Res.
107:810–817. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li H and Yang BB: Stress response of
glioblastoma cells mediated by miR-17-5p targeting PTEN and the
passenger strand miR-17-3p targeting MDM2. Oncotarget. 3:1653–1668.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Y, Chen A, Guo F and Xia Y:
Expression and clinical significance of PTEN protein in
osteosarcoma. Chinese-German J Clin Oncol. 5:296–299. 2008.
View Article : Google Scholar
|
|
32
|
Li J, Yen C, Liaw D, Podsypanina K, Bose
S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al:
PTEN, a putative protein tyrosine phosphatase gene mutated in human
brain, breast and prostate cancer. Science. 275:1943–1947. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Di Cristofano A and Pandolfi PP: The
multiple roles of PTEN in tumor suppression. Cell. 100:387–390.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Naguib A and Trotman LC: PTEN plasticity:
How the taming of a lethal gene can go too far. Trends Cell Biol.
23:374–379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Seront E, Pinto A, Bouzin C, Bertrand L,
Machiels JP and Feron O: PTEN deficiency is associated with reduced
sensitivity to mTOR inhibitor in human bladder cancer through the
unhampered feedback loop driving PI3K/Akt activation. Br J Cancer.
109:1586–1592. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Levine RA, Forest T and Smith C: Tumor
suppressor PTEN is mutated in canine osteosarcoma cell lines and
tumors. Vet Pathol. 39:372–378. 2002. View Article : Google Scholar : PubMed/NCBI
|
